Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
出版年份 2023 全文链接
标题
Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
作者
关键词
-
出版物
Cancer Medicine
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-05-11
DOI
10.1002/cam4.6033
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Recent advances in systemic therapy for hepatocellular carcinoma
- (2022) Huajun Zhang et al. Biomarker Research
- Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
- (2022) Anthony B. El-Khoueiry et al. BMC CANCER
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
- (2022) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
- (2022) Antonio D’Alessio et al. HEPATOLOGY
- Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations
- (2022) Anthony C. Bejjani et al. JOURNAL OF CLINICAL ONCOLOGY
- Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
- (2022) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study
- (2022) Eleni Gkika et al. Cancers
- Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database
- (2022) Haidong Zhang et al. BMC GASTROENTEROLOGY
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
- (2022) Robin Kate Kelley et al. LANCET ONCOLOGY
- LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
- (2022) R.S. Finn et al. ANNALS OF ONCOLOGY
- Comparative assessment of early mortality risk upon immunecheckpoint inhibitors alone or in combinations with other agents across solid malignancies: a systematic review and meta-analysis
- (2022) Giuseppe Viscardi et al. EUROPEAN JOURNAL OF CANCER
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
- (2021) Angelo Dipasquale et al. Journal of Hepatocellular Carcinoma
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
- (2021) Peter R Galle et al. LANCET ONCOLOGY
- Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
- (2021) Arndt Vogel et al. Liver Cancer
- On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
- (2021) Hung-Wei Wang et al. Cancers
- Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
- (2021) Alessandro Di Federico et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Patients’ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life
- (2021) Léa Muzellec et al. Cancers
- Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
- (2021) Alessandro Rizzo et al. Frontiers in Oncology
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Portal hypertensive gastropathy is associated with iron deficiency anemia
- (2020) Benedikt Simbrunner et al. WIENER KLINISCHE WOCHENSCHRIFT
- The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Sadaf G Sepanlou et al. Lancet Gastroenterology & Hepatology
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events
- (2020) Changhoon Yoo et al. LIVER INTERNATIONAL
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study
- (2020) Hyung‐Don Kim et al. LIVER INTERNATIONAL
- Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
- (2020) David J. Pinato et al. Cancers
- Guidelines on the management of ascites in cirrhosis
- (2020) Guruprasad P Aithal et al. GUT
- Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
- (2020) Giuseppe Cabibbo et al. Cancers
- Systemic treatment of HCC in special populations
- (2020) Lorenza Rimassa et al. JOURNAL OF HEPATOLOGY
- Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis
- (2019) Nicolas M. Intagliata et al. GASTROENTEROLOGY
- Hepatorenal Syndrome
- (2019) Claire Francoz et al. Clinical Journal of the American Society of Nephrology
- 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
- (2019) KLCA Korean Liver Cancer Association et al. Gut and Liver
- Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
- (2019) Teiji Kuzuya et al. HEPATOLOGY RESEARCH
- Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
- (2019) Kazuomi Ueshima et al. Cancers
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
- (2018) Haider H. Samawi et al. Cancer Medicine
- Burden of Liver Diseases in the World
- (2018) Sumeet K. Asrani et al. JOURNAL OF HEPATOLOGY
- Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
- (2018) Atsushi Hiraoka et al. Liver Cancer
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Hepatitis B virus infection and alcohol consumption
- (2017) Ayako Iida-Ueno et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
- (2017) Atsushi Hiraoka et al. Liver Cancer
- Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
- (2017) Andrew X. Zhu et al. JAMA Oncology
- Hepatic encephalopathy
- (2017) Peter Ferenci Gastroenterology Report
- Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma
- (2016) Anthony W H Chan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
- (2015) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Prognosis of advanced hepatocellular carcinoma
- (2015) Xavier Adhoute et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Liver cancer: Approaching a personalized care
- (2015) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The State of US Health, 1990-2010
- (2013) Christopher J. L. Murray JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Epidemiology of Hepatocellular Carcinoma
- (2013) Sahil Mittal et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
- (2011) Katherine A. McGlynn et al. Clinics in Liver Disease
- Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis
- (2011) Annalisa Berzigotti et al. HEPATOLOGY
- Potential Precipitating Factors of Esophageal Variceal Bleeding: A Case–Control Study
- (2010) Wei-Chih Liao et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?
- (2010) Fidel-David Huitzil-Melendez et al. JOURNAL OF CLINICAL ONCOLOGY
- Cirrhotic Cardiomyopathy
- (2010) Enrico M. Zardi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Surveillance for hepatocellular carcinoma: in whom and how?
- (2010) Hashem B. El-Serag et al. Therapeutic Advances in Gastroenterology
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatic Encephalopathy: Pathophysiology and Emerging Therapies
- (2009) Vinay Sundaram et al. MEDICAL CLINICS OF NORTH AMERICA
- Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials
- (2008) S. Collette et al. ANNALS OF ONCOLOGY
- A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy
- (2008) Thomas Yau et al. CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now